Royal Philips, the parent company of Philips Healthcare, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for version 9.0 of its IntelliSpace Portal image analytics platform, including several new radiology applications.
Available outside of the U.S. market since November 2016, IntelliSpace Portal 9.0 features additional applications for longitudinal brain mapping, multimodality tumor tracking, and lung nodule assessment, according to the vendor. Designed for analyzing brain images to support the evaluation of neurological disorders over time, longitudinal brain imaging (LoBI) can help clinicians monitor disease progression in patients with neurodegenerative disorders such as stroke, Alzheimer's disease, and multiple sclerosis, Philips said.
Philips has also incorporated quantitative European Association for the Study of the Liver (qEASL) tumor volume measurement capability within its multimodality tumor tracking application. The new method for MRI and CT scans offers a visual indication of how cells are responding to therapy, the company said.
In addition, Philips has garnered FDA clearance for lung nodule assessment, an IntelliSpace application that provides quantitative and characterization information about lung nodules in a single CT study or over time during the course of multiple thoracic studies, the firm said.
